New Strong Sell Stocks for September 16th

Zacks added AGCO, Boston Scientific and Bath & Body Works to its Rank #5 (Strong Sell) list following downward revisions to current-year earnings estimates. Consensus EPS estimates fell 8.1% for AGCO, 1.8% for Boston Scientific and 11.6% for Bath & Body Works over the past 60 days. The revisions signal deteriorating near-term earnings expectations, with the sharpest negative change affecting Bath & Body Works.

Analysis

This is a low-information sell-side screen rather than a fundamental catalyst; revisions can amplify existing momentum through quant/rank-driven flows but do not independently establish a change in intrinsic value. The actionable distinction is dispersion: AGCO and BBWI have materially larger estimate-reset signals than BSX, while BSX’s relatively modest revision is more likely to be absorbed unless it precedes a procedure-volume, pricing, or product-cycle miss. Avoid extrapolating the publisher’s rating into a broad sector call.

For AGCO, the relevant 1-3 month risk is that lower earnings expectations lag a further dealer-inventory correction and weaker farm-income/crop-price economics. A prolonged equipment downcycle would pressure higher-fixed-cost OEM margins and likely redirect demand toward replacement parts and precision-agriculture upgrades; CNH Industrial (CNH) is the cleaner read-through short, while Deere (DE) could prove relatively defensive if its premium installed base sustains aftermarket revenue.

BBWI’s estimate reset is more consequential because specialty retail earnings are highly sensitive to promotional intensity and traffic: even modest comparable-sales weakness can create disproportionate gross-margin deleveraging. The contrarian risk is that a low-expectations setup into holiday selling can produce a sharp squeeze if promotions clear inventory without sacrificing merchandise margin; weekly traffic, discount depth, and inventory-to-sales are required before pressing a directional short. BSX is not an attractive short solely on this signal: medtech tends to receive support from recurring procedure demand and product mix, and the revision magnitude does not yet indicate a broken earnings setup.

Near-term price moves may be modest because the source is widely available and backward-looking. The higher-value catalyst path is the next earnings cycle: guidance cuts, dealer inventory commentary, BBWI gross-margin outlook, or BSX procedure-growth deceleration would validate downside over 1-3 months; stable guidance and improving estimate breadth would falsify the thesis.

Key Decisions for Investors

• Watch, do not initiate, BSX short on this item alone. Escalate only if the next report shows procedure-growth or operating-margin guidance below consensus; absent that, the risk/reward is unfavorable given the limited estimate change.
• Use a 1-3 month relative-value screen: short AGCO versus long DE only if AGCO dealer inventories continue rising and management cuts full-year margin/production assumptions. Exit on stabilized dealer inventory or a crop-price/farm-income rebound; target a 8-12% relative move with a 4-5% stop.
• Treat BBWI as an earnings-event watch rather than an immediate short. Consider a defined-risk bearish put spread 4-8 weeks before results only if channel checks show weak traffic plus elevated promotions; invalidate if inventory turns improve and gross-margin guidance is maintained.
• Monitor CNH as a secondary negative read-through from an AGCO-specific downgrade cycle, but require confirmation from OEM order books and dealer commentary before adding exposure. Broad agricultural-equipment shorts are vulnerable to a rapid commodity-price recovery or fiscal support for farm income.